In Brief: Sandoz
This article was originally published in The Tan Sheet
Executive Summary
Sandoz: Receives Aug. 9 NDA approval for reformulation of Tavist-D tablets to bilayer, film-coated capsules. Product strength and ingredients will remain unchanged. Sandoz awaits FDA approval of a common cold indication for Tavist-D and Tavist-1; the Nonprescription and Pulmonary-Allergy Drugs Advisory Committees concluded last year that company data support the new indication ("The Tan Sheet" Nov. 20, 1995, p. 5)...